Gilman Law Launches GenVec, Inc. (NASDAQ:GNVC) Securities Fraud Class Action Investigation
The Naples Florida office of Gilman Law LLP, a leading national securities law firm, is actively investigating potential securities fraud allegations that GenVec, Inc. (“GenVec”) and certain of its officers and directors violated the Securities Exchange Act of 1934, by issuing materially false or misleading information to investors before announcing on March 29, 2011, that it was discontinuing its Phase III clinical trial of TNFerade in patients with locally advances pancreatic cancer. GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company based Gaithersburg, Maryland which claims to use differentiated, proprietary technologies to create therapeutics and vaccines.
Attorneys at Gilman Law have combined experience litigating securities and other class action cases for over 32 years, and have been involved in all major aspects of securities litigation. Gilman Law specializes in cases involving stock manipulation, securities fraud, investment fraud, and shareholder rights violations. If you purchased or otherwise acquired shares of GenVec, Inc. between March 12, 2009, and March 29, 2010, you may contact Gilman Law LLP to discuss your rights, including as to recovery of your losses or to obtain additional information.
Gilman Law has extensive experience representing both individual and institutional investors in securities class action suits. Gilman Law has recovered over a billion dollars for its clients and can help you recover any losses that you have incurred as a result of GenVec’s fraudulent practices. For a free evaluation of your case or to obtain additional information, please complete the Investor Certification or CALL TOLL FREE (888) 252-0048.